{"id":"NCT01629966","sponsor":"Forest Laboratories","briefTitle":"Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder","officialTitle":"A Double-blind, Placebo-Controlled Fixed-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06-30","primaryCompletion":"2014-02-28","completion":"2014-03-31","firstPosted":"2012-06-28","resultsPosted":"2019-12-18","lastUpdate":"2019-12-18"},"enrollment":680,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Anxiety Disorder"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Vilazodone","otherNames":[]},{"type":"DRUG","name":"Vilazodone","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Vilazadone 20mg","type":"EXPERIMENTAL"},{"label":"Vilazodone 40mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)","primaryOutcome":{"measure":"Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score","timeFrame":"Baseline to Week 8","effectByArm":[{"arm":"Placebo","deltaMin":13.1,"sd":7.93},{"arm":"Vilazadone 20mg","deltaMin":12,"sd":7.13},{"arm":"Vilazodone 40mg","deltaMin":11.2,"sd":7.46}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0830"},{"comp":"OG000 vs OG002","p":"0.0156"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":37,"countries":["United States"]},"refs":{"pmids":["27486544","25891440"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":221},"commonTop":["Nausea","Diarrhoea","Headache","Dizziness","Upper respiratory tract infection"]}}